Severe Hypertriglyceridemia (SHTG) - Pipeline Insight, 2025: Emerging Therapies Target Lipid Metabolism and Cardiovascular Risk Reduction | DelveInsight

Severe Hypertriglyceridemia (SHTG), characterized by triglyceride levels exceeding 500 mg/dL, significantly elevates the risk of acute pancreatitis and cardiovascular complications. Despite the availability of fibrates, statins, and omega-3 fatty acids, many patients fail to achieve optimal triglyceride control, highlighting the need for more effective, targeted treatments.

DelveInsight's "Severe Hypertriglyceridemia (SHTG) - Pipeline Insight, 2025" analyzes over 10 active pipeline candidates, including next-generation apoC-III inhibitors, ANGPTL3 inhibitors, siRNA-based therapies, and combination lipid-lowering agents. Key biopharma companies such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Kowa Research Institute, and others are driving innovation with therapies designed to address the genetic and metabolic underpinnings of SHTG.

The report provides detailed insights into clinical-stage programs, trial outcomes, and emerging mechanisms of action aimed at reducing triglyceride levels, mitigating pancreatitis risk, and improving cardiovascular outcomes. Notable developments include antisense oligonucleotides targeting apoC-III and siRNA agents with prolonged lipid-lowering effects.

With a focus on personalized therapy and precision lipid management, the SHTG treatment landscape is shifting toward more effective and sustainable triglyceride control. This evolving pipeline signals a new era in the management of lipid disorders, offering hope for improved patient outcomes in both primary and secondary prevention settings.

Interested in learning more about the current treatment landscape and the key drivers shaping the severe hypertriglyceridemia pipeline? Click here: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
• DelveInsight's severe hypertriglyceridemia pipeline analysis depicts a strong space with 8+ active players working to develop 10+ pipeline drugs for severe hypertriglyceridemia treatment.
• The leading severe hypertriglyceridemia companies include Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Kowa Research Institute, Mochida Pharmaceutical, Acasti Pharma, NorthSea Therapeutics, Matinas BioPharma, and others are evaluating their lead assets to improve the severe hypertriglyceridemia treatment landscape.
• Key severe hypertriglyceridemia pipeline therapies in various stages of development include ARO-APOC3, Olezarsen, BIO89-100, Evinacumab, K-877, Ethyl Icosapentate, CaPre, SEFA-1024, MAT9001, and others.
• In May 2025, Ionis Pharmaceuticals announced positive topline results from the Essence study of olezarsen in patients with moderate hypertriglyceridemia and ASCVD risk. The trial met its primary endpoint, showing significant triglyceride reductions of 61% and 58% at 6 months with 80 mg and 50 mg doses, respectively. Most participants reached normal TG levels (

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.